Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
PetIQ acquisition of MYOS
We advised Bansk Group and its portfolio company PetIQ on the transaction
Integer Holdings $5.7 billion sale to KKR
We are advising Integer on the transaction
athenahealth $500 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Inotiv emerges from chapter 11
We advised an ad hoc group of first-lien lenders in connection with Inotiv’s chapter 11 proceedings
Financing for Bridgepoint acquisition of GBA Group
We are advising the lenders on the transaction
REGENXBIO $115 million equity offering
We advised the joint book-running managers and underwriters on the offering
Ascentage Pharma $200 million at-the-market offering
We advised the sales agents on the offering
GenFleet Therapeutics HK$471.8 million placement of new H shares
We advised GenFleet Therapeutics on the placement
Clarivate sale of Life Sciences & Healthcare segment to Altaris
We are advising Clarivate on the transaction
Alebund Pharmaceuticals HK$1.28 billion IPO
We advised Alebund Pharmaceuticals on its IPO and HKEX listing